Solid Biosciences Announces Licensing Agreement with Kinea Bio for the Use of Proprietary Next-Generation Capsid AAV-SLB101

Core Insights - Solid Biosciences has entered into a non-exclusive worldwide license and collaboration agreement with Kinea Bio for the use of its proprietary capsid, AAV-SLB101, to develop KNA-155, a gene therapy targeting dysferlinopathy [1][2] - Solid will receive an upfront payment and is eligible for additional milestone payments and tiered royalties on net sales [2] - AAV-SLB101 is designed for enhanced muscle tropism and reduced liver biodistribution, showing promising results in preclinical studies and early clinical trials [3][7] Company Overview - Solid Biosciences focuses on developing precision genetic medicines for neuromuscular and cardiac diseases, with a diverse pipeline including therapies for Duchenne muscular dystrophy and other rare diseases [8][9] - The company aims to license AAV-SLB101 broadly to various institutions and companies pursuing treatments for rare diseases, having already established over 25 agreements [7] Collaboration Details - The agreement allows Kinea Bio to utilize AAV-SLB101 as the delivery mechanism for KNA-155, which is currently advancing into IND-enabling preclinical activities [2] - Both companies express confidence in the potential of AAV-SLB101 to deliver safe and effective therapies for patients with dysferlinopathies [6]